Oncolytics Biotech (ONCY)
(Real Time Quote from BATS)
$0.96 USD
0.00 (0.21%)
Updated Sep 9, 2024 12:33 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ONCY 0.96 0.00(0.21%)
Will ONCY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ONCY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ONCY
Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
ONCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Novartis (NVS) to Report Q1 Earnings: What to Expect?
After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)
Other News for ONCY
Oncolytics Biotech? to Participate in Fireside Chats at Two Investment Conferences in September
Optimistic Outlook for Oncolytics Biotech with Continued Buy Rating Amidst Promising Trial Results
Sernova Corp. Announces Appointment of New Chief Executive Officer
Sernova names Rigby as new CEO
Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY), R1 RCM (RCM) and Lumos Pharma (LUMO)